Analysis of the Clinical Distribution and Resistance Rate of ESBLs Escherichia Coli
Objective To describe the information and clinical distribution of ultra-broad spectrum β-lactamase Escherichia coli(ESBL-EC),analyze the resistance of ESBL-EC,and provide a basis for the prevention and control of nosocomial infection.Methods Patients diagnosed with ESBL-EC infection in the Third Hospital of Xiamen from 2017 to 2022 were selected to collect the information of patients and ESBL-EC strains,and analyze their infection status,clinical characteristics and drug resistance.Results A total of 929 patients with ESBL-EC infection were diagnosed,and the gender and age differences between community infection and hospital infection were statistically significant(P<0.001).The detection rate of ESBL-EC was 38.52%,and the detection rate showed an increasing trend year by year(P<0.001).The ESBL-EC was mainly derived from the general surgery department(19.38%).The ESBL-EC was mainly isolated from urine(43.38%).In ESBL-EC against aztreonam,nitrofurantoin,cotrimoxazole,cefepime,and tobramycin,the resistance rate decreased,the difference was statistically significant(P<0.05).The resistance rate to ciprofloxacin,ceftazidime and gentamicin showed an increasing trend,and the difference was statistically significant(P<0.05).The resistance rate of ESBL-EC to ampicillin,ampicillin/sulbactam,nitrofurantoin,ciprofloxacin,gentamicin,cephalosporin,tobramycin,and levofloxacin were higher than those of the community infection,the difference was statistically significant(P<0.05).Conclusion The detection rate of ESBL-EC has increased year by year.The resistance situation of ESBL-EC resistance is severe,and various infection prevention and control measures should be strengthened to reduce the risk of cross-infection;antimicrobial drugs should be rationally used reasonably to reduce the production of ESBL-EC resistant strains.
万方数据
维普
